1,3-Dimethyl-indol-5-ol, Physostigmol | 10102-95-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1,3-Dimethyl-indol-5-ol, Physostigmol
• 英文别名: 1,3-dimethyl-indol-5-ol；1,3-Dimethyl-1h-indol-5-ol；1,3-dimethylindol-5-ol
• CAS: 10102-95-1
• 化学式: C₁₀H₁₁NO
• 分子量: 161.203
• InChiKey: YIHBZFHOBSCEFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  25.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 生成 1,3-Dimethyl-indol-5-ol, Physostigmol
  参考文献：
  名称：

  Straus, Justus Liebigs Annalen der Chemie, 1914, vol. 406, p. 337

  摘要：

  DOI：

文献信息

• Therapeutic diphenyl ether ligands
  申请人：Fliri J. Anton

  公开号：US20060058361A1

  公开（公告）日：2006-03-16

  This invention is directed to compounds of formula Ia, Ib or Ic and to pharmaceutical compositions thereof: or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are defined in the specification; and, in which the dashed line represents an optional double bond. The invention is also directed to methods of treating, diagnosing, and preventing disorders of the central nervous system that are associated with 5HT receptors, including obesity, attention deficit disorder, migraine, depression, epilepsy, anxiety, Alzheimer's disease, withdrawal from drug abuse, pain, schizophrenia, stress-related disorders, panic disorder, sleep disorders, phobias, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, stress-induced gastrointestinal dysfunction, stress-induced cardiovascular dysfunction, and sexual dysfunction.

  该发明涉及式Ia、Ib或Ic的化合物，以及其药物组成物：或其前药和药用可接受载体，其中R基在规范中定义；以及虚线代表可选的双键。该发明还涉及治疗、诊断和预防与5HT受体相关的中枢神经系统疾病的方法，包括肥胖、注意缺陷障碍、偏头痛、抑郁症、癫痫、焦虑、阿尔茨海默病、戒毒、疼痛、精神分裂症、应激相关疾病、恐慌症、睡眠障碍、恐惧症、强迫症、创伤后应激综合征、免疫系统抑郁、应激引起的胃肠功能障碍、应激引起的心血管功能障碍和性功能障碍。
• Agents useful for reducing amyloid precursor protein and treating demantia and methods of use thereof
  申请人：——

  公开号：US20040138282A1

  公开（公告）日：2004-07-15

  The present invention provides compounds and methods of administering compounds to a subject taht can reduce &bgr;APP production and that is not toxic in a wide range of dosages. The present invention also provides non-carbamate compounds and methods of administering such compounds to a subject that can reduce &bgr;APP production and that is not tocix in a wide range of dosages. It has been discovered that either the racemic or enantiomerically pure non-carbamate compounds can be used to decrease &bgr;APP production.

  本发明提供了化合物和给予这些化合物给受试者的方法，可以减少βAPP的产生，并且在广泛剂量范围内不具有毒性。本发明还提供了非碳酸酯化合物和给予这些化合物给受试者的方法，可以减少βAPP的产生，并且在广泛剂量范围内不具有毒性。已经发现无论是混合物还是对映纯的非碳酸酯化合物都可以用于降低βAPP的产生。
• [EN] KRAS INHIBITOR CONJUGATES<br/>[FR] CONJUGUÉS D'INHIBITEURS DE KRAS
  申请人：ERASCA INC

  公开号：WO2022266206A1

  公开（公告）日：2022-12-22

  The present application provides conjugates of protein-binding ligands, in particular G12D mutant KRAS ligands, with ubiquitin ligase ligands and methods for treating diseases such as cancer.

  本申请提供了蛋白质结合配体的共轭物，尤其是G12D突变KRAS配体与泛素连接酶配体，并提供了用于治疗癌症等疾病的方法。
• Straus, Justus Liebigs Annalen der Chemie, 1913, vol. 401, p. 361
  作者：Straus

  DOI：——

  日期：——
• AGENTS USEFUL FOR REDUCING AMYLOID PRECURSOR PROTEIN AND TREATING DEMANTIA AND METHODS OF USE THEREOF
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA,as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1349858A2

  公开（公告）日：2003-10-08